Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06564389 · ClinicalTrials.gov registry record · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
A Phase 1 study of Atopic Dermatitis and Healthy Participants, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
- 2
- Study locations
NCT06564389: Recruiting Phase 1 study of Atopic Dermatitis and Healthy Participants, sponsored by Pfizer.
NCT06564389 is a Phase 1 study of Atopic Dermatitis and Healthy Participants that is actively recruiting participants, run by Pfizer. The registered enrollment target is 119 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06564389, a Phase 1 study of Atopic Dermatitis and Healthy Participants, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other impo
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PF-07832837
Study Locations (2)
California
- Anaheim Clinical Trials, LLC - Anaheim
Florida
- Miami Dermatology and Laser Research - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2027-06-02 |
| Phase | Phase 1 |
What NCT06564389 shows while recruiting
NCT06564389 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06564389 reports a single indexed study location in California, Florida.
Frequently Asked Questions
What is clinical trial NCT06564389 about?
NCT06564389 is a clinical study titled "FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients". The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in pa...
What is the current status of trial NCT06564389?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2024-11-05. Estimated completion is 2027-06-02.
What conditions does trial NCT06564389 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Healthy Participants.
What interventions are being tested in trial NCT06564389?
The interventions under investigation include: Placebo (OTHER), PF-07832837 (DRUG).
Who is sponsoring clinical trial NCT06564389?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06564389 being conducted?
This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06564389's enrollment target sits among peer trials
119 80th of 150 higher than 71 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
-
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
- NCT06930625 · 119 participants · Phase 3
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI